Anticancer
Proteologics' proven, proprietary ubiquitin Target & Drug Discovery Platform offers a very broad potential. This potential has already materialized into two programs in cancer therapy, in collaboration with Teva Pharmaceutical. These programs focusing on two distinct major biochemical pathways initiated in May 2005 and have already yielded a cancer target, a novel HTS assay & several small molecule inhibitors that have been shown to stabilize the specific ubiquitination substrate of interest, in cells.

New Programs
There is a known causative link between the ubiquitin system and many other major human diseases including many cancers, neuro-degenerative conditions (such as Alzheimer's and Parkinson's diseases), cystic fibrosis and immune disorders. Based on Proteologics' leading position in ubiquitin based target and drug discovery, additional research programs in cancer, CNS diseases and anti-viral are currently under discussion with potential corporate partners.